A 12wk dual therapy (GS-7977+Riba) against Genotype 1 and 8wk dual therapy against GT 2/3 will never be used again in trials or off-label use.
It is also a legitimate question to ask whether the triple combo will ever be used after an expected 2016 launch. Look at this afternoon's late-breaking abstract for GS-7977+BMS790052. The results are amazing without Riba, which is a good source of SAE. Vertex's VX-135 + GSK-2336805 could do even better because they are testing a 12 week regimen, not 24 wk one as in the 7977+052 trial. I trust Peter Mueller's words: VX-135 is as good as any NS5B inhibitors around in both safety and efficacy, and GSK's NS5A inhibitor is also one of the best.